Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
29 hedge funds and large institutions have $18.1M invested in Cymabay Therapeutics in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 11 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
17% less funds holding
Funds holding: 35 → 29 (-6)
21% less capital invested
Capital invested by funds: $23M → $18.1M (-$4.82M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$490K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$115K |
| 3 |
Renaissance Technologies
New York
|
+$99.3K |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$71.6K |
| 5 |
HF
Hoxton Financial
Shepherdstown,
West Virginia
|
+$42.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.62M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$776K |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$485K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$107K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$42K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $4K | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $4K | +$4.03K | +2,473 | New |
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | +$2.55K | +1,562 | New |
|
|
AC
29
Armistice Capital
New York
| – | -$1.62M | -836,000 | Closed |
|
|
GTC
30
Ghost Tree Capital
New York
| – | -$776K | -400,000 | Closed |
|
|
IHM
31
Iguana Healthcare Management
New York
| – | -$485K | -250,000 | Closed |
|
|
32
BNP Paribas Financial Markets
Paris,
France
| – | -$107K | -55,000 | Closed |
|
|
BFM
33
Boothbay Fund Management
New York
| – | -$42K | -21,897 | Closed |
|
|
TC
34
TFS Capital
West Chester,
Pennsylvania
| – | -$41K | -21,263 | Closed |
|
35
Balyasny Asset Management
Chicago,
Illinois
| – | -$24K | -12,600 | Closed |
|
36
Creative Planning
Overland Park,
Kansas
| – | -$23K | -12,000 | Closed |
|
37
Mariner
Overland Park,
Kansas
| – | -$23K | -12,000 | Closed |
|
38
Walleye Trading
New York
| – | -$8K | -4,100 | Closed |
|
39
Morgan Stanley
New York
| – | -$5K | -2,568 | Closed |
|
CBAY Hedge Fund Activity: Q4 2015 in Review
29 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2015, worth a combined $18.1M — down 21% from $23M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CBAY and 5 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Sabby Management, adding an estimated $490K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.62M sold.
- 29 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2015, down from 35 in Q3 2015.
- Funds reported $18.1M of Cymabay Therapeutics stock for Q4 2015, down 21% quarter-over-quarter.
- 5 funds opened new Cymabay Therapeutics positions in Q4 2015 and 11 closed out, a net change of -6 holders.
- The largest Cymabay Therapeutics buyer in Q4 2015 was Sabby Management, an estimated $490K added.
- The largest Cymabay Therapeutics seller in Q4 2015 was Armistice Capital, an estimated $1.62M sold.
Based on aggregated 13F filings for Q4 2015.